Dupixent available for asthma patients 12 and older

Dupixent (Dupilumab),  is a monoclonal antibody designed for the treatment of allergic diseases such as eczema and asthma by blockage of IL-4Rα, dupilumab modulates signaling of both the interleukin 4 and interleukin 13 pathways, which are allergic pathways.

Indicated for 12 and older for asthma, contact our office if you are interested in a non-steroidal treatment for your child’s moderate to severe asthma.